Advanced Cell Technology and Wisconsin Alumni Research Foundation Announce Commercial License Agreement

The expanded agreement grants Advanced Cell rights to the commercial use of human embryonic stem cells (hESCs) to develop human therapies, with the exception of neuronal, pancreatic beta cells, and cardiac applications, and enables the marketing of a broad array of research products.

Source: Advanced Cell Technology